70 completed, 18 active not recruiting, 14 terminated, 7 recruiting. 72 Phase 2, 57 Phase 1, 4 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow AZD 6244: new trials by email Literature Review of AZD 6244 trials Research Report on AZD 6244
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-07-15 | 2026-07-16 |
| Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 | Recruiting | Girish Dhall, MD | 30 | 2026-06-09 | 2026-10-02 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2025-08-27 | 2026-05-29 |
| Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children Selumetinib - Plexiform Neurofibromas (PN) | Phase 2 | Not yet recruiting | West China Hospital | 50 | 2025-01-01 | 2025-01-08 |
| The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule Selumetinib - Neurofibromatosis 1 | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 19 | 2024-09-30 | 2024-10-01 |
| Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule Selumetinib - Neurofibromatosis 1 | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 33 | 2024-09-30 | 2024-10-01 |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study Selumetinib, Placebo - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 2 | Withdrawn | AstraZeneca | 2023-08-31 | 2023-08-14 | |
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN Selumetinib granule formulation, Selumetinib capsule formulation - Neurofibromatosis Type 1 | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 36 | 2022-01-21 | 2026-08-13 |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN) | Phase 3 | Active not recruiting | AstraZeneca | 145 | 2021-11-19 | 2026-03-23 |
| Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas Selumetinib - Neurofibromatosis Type 1 | Phase 1 | Active not recruiting | AstraZeneca | 24 | 2021-07-21 | 2026-08-20 |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Selumetinib - Neurofibromatosis 1, Neurofibroma Plexiform | Phase 1 | Active not recruiting | AstraZeneca | 32 | 2020-12-16 | 2026-08-18 |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. Arm A - Olaparib, ARM B - durvalumab plus selumetinib, ARM C FOLFIRI - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 307 | 2020-12-07 | 2025-07-25 |
| Selumetinib Paediatric NF1 Japan Study Selumetinib - Neurofibromatosis Type 1 | Phase 1 | Completed | AstraZeneca | 12 | 2020-08-31 | 2023-04-26 |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 21 | 2019-10-02 | 2026-05-27 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2019-09-26 | 2024-04-04 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) Osimertinib, Savolitinib, Gefitinib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 247 | 2019-06-25 | 2025-01-30 |
Showing 20 of 122. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (21) · Neurofibromatosis 1 (19) · Melanoma (11) · Neurofibroma, Plexiform (11) · Lung Neoplasms (8) · Breast Neoplasms (7) · Colorectal Neoplasms (7) · Neoplasm Metastasis (7) · Neoplasms (7) · Pancreatic Neoplasms (5) · Carcinoma, Hepatocellular (4) · Biliary Tract Neoplasms (3) · Colonic Neoplasms (3) · Ependymoma (3) · Gallbladder Neoplasms (3)
AstraZeneca (39) · National Cancer Institute (NCI) (32) · M.D. Anderson Cancer Center (5) · Merck Sharp & Dohme LLC (3) · Beijing Tiantan Hospital (2) · Canadian Cancer Trials Group (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · The Christie NHS Foundation Trust (2) · UNICANCER (2) · University of Alabama at Birmingham (2) · University of Birmingham (2) · Academic and Community Cancer Research United (1) · AeRang Kim (1) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Cancer Research UK (1)
United States (78) · United Kingdom (24) · Canada (15) · France (13) · Netherlands (11) · Spain (10) · Brazil (8) · Germany (7) · Italy (7) · Japan (7) · Poland (6) · Bulgaria (5) · China (5) · Denmark (5) · Hungary (5)
Brigitte C Widemann, M.D. (3) · Eleanor Lisbon, MD (3) · Gabriella Mariani, MD (3) · AeRang Kim, MD, PhD (2) · Arun Rajan, M.D. (2) · Ian Smith, MD (2) · Paul Chapman (2) · Tanios Bekaii-Saab (2) · Thomas C Marbury, MD (2) · Zhiquan Huang, doctoral (2) · Alan Ho, M.D., PHD (1)
PMID 28029918, PMID 32187457, PMID 15683544, PMID 17105749, PMID 21996156, PMID 22353803, PMID 26851632, PMID 28230061, PMID 28409229, PMID 28985960, PMID 29528792, PMID 31010905, PMID 31582003, PMID 32379297, PMID 33354735, PMID 33863389, PMID 34541874, PMID 21519026, PMID 22293660, PMID 22972589, PMID 23077008, PMID 23200175, PMID 23261356, PMID 23406027, PMID 23735514, PMID 24178622, PMID 24938562, PMID 25516890, PMID 25667274, PMID 25887099, PMID 25892646, PMID 26028668, PMID 26059332, PMID 26125448, PMID 26410619, PMID 26666244, PMID 26802155, PMID 26837474, PMID 26912134, PMID 27681866, PMID 27751676, PMID 27921276, PMID 27978579, PMID 28264648, PMID 28424891, PMID 28492898, PMID 29045535, PMID 29718344, PMID 30317534, PMID 31151904
N01CM62208 (5), 2016 (3), N01CM00070 (3), N01CM00071 (3), N01CM00100 (3), N01CM62201 (3), N01CM62206 (3), P30CA076292 (3), 2014 (2), N01CM62207 (2), P30CA008748 (2), P30CA015083 (2), U10CA027469 (2), U10CA180868 (2), UM1CA186686 (2)